Search results
Showing 301 to 305 of 305 results for eq-5d
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
New UK valuation study for EQ-5D quality of life questionnaire to start this year
Work to get underway in the Autumn on new valuation study for the EQ-5D-5L questionnaire
For the last three years, NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health
Researchers wanted to study the public's views of health-related quality of life
Applications close on Wednesday 4 March 2020